Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press141110.17650/1726-9776-2020-16-4-61-81DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак почкиРекомендации по лечению пациентов с прогрессирующим или метастатическим почечно-клеточным раком комбинацией ленватиниба и эверолимусаРекомендации по лечению пациентов с прогрессирующим или метастатическим почечно-клеточным раком комбинацией ленватиниба и эверолимусаGrandeE.
Spain
GlenH.GlenН.
United Kingdom
AllerJ.
Spain
ArgenzianoG.
Italy
LamasM. J.
Spain
RuszniewskiP.
France
ZamoranoJ. L.
Spain
EdmondsK.
United Kingdom
SarkerS.
United Kingdom
StaehlerM.
Germany
LarkinJ.
United Kingdom
3012202016461810902202109022021https://oncourology.abvpress.ru/oncur/article/view/1411

.

На сегодняшний день существует несколько вариантов терапии 2-й линии для пациентов с почечно-клеточным раком после неудачи 1-й линии терапии ингибиторами тирозинкиназ. Недавно были одобрены для лечения кабозантиниб, ниволумаб и комбинация ленватиниб + эверолимус. Отсутствие надежных биомаркеров, а также ограниченность данных проспективных сравнений различных препаратов затрудняют выбор тактики лечения 2-й линии в рутинной клинической практике.

В настоящем обзоре мы описываем профиль безопасности комбинации ленватиниб + эверолимус при почечно-клеточном раке. Данная комбинация обеспечила наиболее высокие показатели объективного ответа на терапию, выживаемости без прогрессирования и общей выживаемости в исследованиях с перекрестным дизайном. В то же время профиль безопасности этой комбинации, включая частоту общих и тяжелых нежелательных явлений, процент пациентов, которым потребовалось снижение дозы или полная отмена лечения, был менее благоприятным по сравнению с доступными вариантами монотерапии. Это позволяет предположить, что более тщательный контроль токсических реакций может способствовать достижению максимальной активности этих двух средств, одновременно защищая пациентов от неоправданного вреда.

Цель — разработка междисциплинарных рекомендаций для пациентов и лиц, осуществляющих уход за ними, перед началом лечения комбинацией ленватиниб + эверолимус, в том числе по контролю терапии с точки зрения повседневной клинической практики.

Основные положения:

•             Комбинация ленватиниба и эверолимуса одобрена для лечения пациентов с почечно-клеточным раком, рефрактерным к терапии ингибиторами тирозинкиназ, на основании высоких показателей объективного ответа, длительной выживаемости без прогрессирования и общей выживаемости.

•             Профиль безопасности этой комбинации включает высокую частоту общих и тяжелых нежелательных явлений, при этом многие пациенты нуждаются в снижении дозы или прекращении лечения. Это позволяет предположить, что более эффективный контроль токсических реакций может способствовать достижению максимальной активности комбинации препаратов, одновременно защищая пациентов от неоправданного вреда.

•             В этой статье мы представили мультидисциплинарные рекомендации по консультированию пациентов и лиц, осуществляющих уход за ними, перед началом лечения ленватинибом в комбинации с эверолимусом, в том числе по контролю терапии с точки зрения повседневной клинической практики.

Публикуется на русском языке с разрешения авторов. Оригинал: Grande E., Glen H., Aller J. et al. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. Expert Opinion on Drug Safety 2017. DOI: 10.1080/14740338.2017.1380624.

коррекция дозыэверолимусленватинибоптимизацияпочечно-клеточный рактерапиябезопасность1. Tilki D., Nguyen H.G., Dall’Era M.A. et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol 2014;66:577-83.Tilki D., Nguyen H.G., Dall’Era M.A. et al. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol 2014;66:577-83.2. Hakimi A.A., Reznik E., Lee C.H. et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell 2016;29:104-16.Hakimi A.A., Reznik E., Lee C.H. et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell 2016;29:104-16.3. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.4. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.5. Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65.Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65.6. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.7. Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.8. Calvo E., Schmidinger M., Heng D.Y. et al. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev 2016;50:109-17.Calvo E., Schmidinger M., Heng D.Y. et al. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treat Rev 2016;50:109-17.9. Iacovelli R., Carteni G., Sternberg C.N. et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 2013;49:2134-42.Iacovelli R., Carteni G., Sternberg C.N. et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. Eur J Cancer 2013;49:2134-42.10. Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:1473-82.Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:1473-82.11. Motzer R.J., Hutson T.E., Ren M. et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17:e4-5.Motzer R.J., Hutson T.E., Ren M. et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17:e4-5.12. Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.13. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-23.Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-23.14. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917-27.Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917-27.15. Cella D., Grunwald V., Nathan P. et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:994-1003.Cella D., Grunwald V., Nathan P. et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:994-1003.16. Houk B.E., Bello C.L., Poland B. et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmaco- dynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71.Houk B.E., Bello C.L., Poland B. et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmaco- dynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71.17. Kumar R., Knick V.B., Rudolph S.K. et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21.Kumar R., Knick V.B., Rudolph S.K. et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21.18. Ornstein M.C., Wood L., Elson P. et al. Clinical effect of dose escalation after disease progression in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2017;15:e275-e80.Ornstein M.C., Wood L., Elson P. et al. Clinical effect of dose escalation after disease progression in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2017;15:e275-e80.19. Rini B.I., Tomita Y., Melichar B. et al. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma. Clin Genitourin Cancer 2016;14:499-503.Rini B.I., Tomita Y., Melichar B. et al. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration in first-line metastatic renal cell carcinoma. Clin Genitourin Cancer 2016;14:499-503.20. Rugo H.S., Hortobagyi G.N., Yao J. et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 2016;27:519-25.Rugo H.S., Hortobagyi G.N., Yao J. et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 2016;27:519-25.21. Boss D.S., Glen H., Beijnen J.H. et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 2012;106:1598-604.Boss D.S., Glen H., Beijnen J.H. et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 2012;106:1598-604.22. Yamada K., Yamamoto N., Yamada Y. et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17:2528-37.Yamada K., Yamamoto N., Yamada Y. et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17:2528-37.23. FDA Approves Drug Combo for Kidney Cancer. Cancer Discov 2016;6:687-8.FDA Approves Drug Combo for Kidney Cancer. Cancer Discov 2016;6:687-8.24. Nair A., Lemery S.J., Yang J. et al. FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin Cancer Res 2015;21:5205-8.Nair A., Lemery S.J., Yang J. et al. FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin Cancer Res 2015;21:5205-8.25. Scott L.J. Lenvatinib: first global approval. Drugs 2015;75:553-60.Scott L.J. Lenvatinib: first global approval. Drugs 2015;75:553-60.26. Kisplyx® (lenvatinib) [EPAR - Product Information. Summary of Product Characteristics, EMEA/H/C/004224 -II/0001]. Eisai Europe Ltd.; 03/03/2017 [25/03/2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004224/WC500216237.pdf.Kisplyx® (lenvatinib) [EPAR - Product Information. Summary of Product Characteristics, EMEA/H/C/004224 -II/0001]. Eisai Europe Ltd.; 03/03/2017 [25/03/2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004224/WC500216237.pdf.27. StatBite: FDA oncology drug product approvals in 2009. J Natl Cancer Inst 2010;102:219.StatBite: FDA oncology drug product approvals in 2009. J Natl Cancer Inst 2010;102:219.28. Lenvima® (lenvatinib) [FDA prescribing information]. Eisai Inc; May 2016 [25/03/2017]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206947s003lbl.pdf.Lenvima® (lenvatinib) [FDA prescribing information]. Eisai Inc; May 2016 [25/03/2017]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206947s003lbl.pdf.29. Dubbelman A.C., Rosing H., Nijenhuis C. et al. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs 2015;33:233-40.Dubbelman A.C., Rosing H., Nijenhuis C. et al. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Invest New Drugs 2015;33:233-40.30. Gupta A., Jarzab B., Capdevila J. et al. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol 2016;81:1124-33.Gupta A., Jarzab B., Capdevila J. et al. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol 2016;81:1124-33.31. Kisplyx® (lenvatinib) [EPAR - Procedural steps taken and scientific information after authorisation, EMA/578759/2016]. Eisai Europe Ltd.; 16/11/2016 [25/03/2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004224/WC500216286.pdf.Kisplyx® (lenvatinib) [EPAR - Procedural steps taken and scientific information after authorisation, EMA/578759/2016]. Eisai Europe Ltd.; 16/11/2016 [25/03/2017]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004224/WC500216286.pdf.32. Al-Marrawi M.Y., Rini B.I., Harshman L.C. et al. International m RCCDC. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to secondline VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013;8:203-9.Al-Marrawi M.Y., Rini B.I., Harshman L.C. et al. International m RCCDC. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to secondline VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol 2013;8:203-9.33. Bracarda S., Sisani M., Marrocolo F. et al. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol 2014;89:386-93.Bracarda S., Sisani M., Marrocolo F. et al. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. Crit Rev Oncol Hematol 2014;89:386-93.34. Escudier B., Michaelson M.D., Motzer R.J. et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014;110:2821-8.Escudier B., Michaelson M.D., Motzer R.J. et al. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014;110:2821-8.35. Porta C., Tortora G., Linassier C. et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol 2012;29:1896-907.Porta C., Tortora G., Linassier C. et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Med Oncol 2012;29:1896-907.36. Sonpavde G., Choueiri T.K., Escudier B. et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 2012;61:307-16.Sonpavde G., Choueiri T.K., Escudier B. et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 2012;61:307-16.37. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.38. Keller K.L., Franquiz M.J., Duffy A.P., Trovato J.A. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 2016.Keller K.L., Franquiz M.J., Duffy A.P., Trovato J.A. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 2016.39. Shumaker R., Aluri J., Fan J. et al. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. J Clin Pharmacol 2015;55:317-27.Shumaker R., Aluri J., Fan J. et al. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. J Clin Pharmacol 2015;55:317-27.40. Shumaker R.C., Zhou M., Ren M. et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol 2014;73:1109-17.Shumaker R.C., Zhou M., Ren M. et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol 2014;73:1109-17.41. Valle J.W., Faivre S., Hubner R.A. et al. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev 2014;40:1230-8.Valle J.W., Faivre S., Hubner R.A. et al. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treat Rev 2014;40:1230-8.42. Lysiak J.J., Kavoussi P.K., Ellati R.T. et al. Angiogenesis therapy for the treatment of erectile dysfunction. J Sex Med. 2010;7:2554-63.Lysiak J.J., Kavoussi P.K., Ellati R.T. et al. Angiogenesis therapy for the treatment of erectile dysfunction. J Sex Med. 2010;7:2554-63.43. Villalba N., Kun A., Stankevicius E., Simonsen U. Role for tyrosine kinases in contraction of rat penile small arteries. J Sex Med. 2010;7:2086-95.Villalba N., Kun A., Stankevicius E., Simonsen U. Role for tyrosine kinases in contraction of rat penile small arteries. J Sex Med. 2010;7:2086-95.44. Bessede T., Massard C., Albouy B. et al. Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors. Ann Oncol 2011;22:2320-4.Bessede T., Massard C., Albouy B. et al. Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors. Ann Oncol 2011;22:2320-4.45. Bessede T., Joly F., Lebret T. Management of side effects of targeted therapies in renal cancer: sexual disorders. Bull Cancer 2011;98:S127-31.Bessede T., Joly F., Lebret T. Management of side effects of targeted therapies in renal cancer: sexual disorders. Bull Cancer 2011;98:S127-31.46. Hautamaki-Lamminen K., Lipiainen L., Beaver K. et al. Identifying cancer patients with greater need for information about sexual issues. Eur J Oncol Nurs 2013;17:9-15.Hautamaki-Lamminen K., Lipiainen L., Beaver K. et al. Identifying cancer patients with greater need for information about sexual issues. Eur J Oncol Nurs 2013;17:9-15.47. Coady D., Kennedy V. Sexual health in women affected by cancer: focus on sexual pain. Obstetric Gynecol 2016;128:775-91.Coady D., Kennedy V. Sexual health in women affected by cancer: focus on sexual pain. Obstetric Gynecol 2016;128:775-91.48. Gilbert E., Perz J., Ussher J.M. Talking about sex with health professionals: the experience of people with cancer and their partners. Eur J Cancer Care 2016;25:280-93.Gilbert E., Perz J., Ussher J.M. Talking about sex with health professionals: the experience of people with cancer and their partners. Eur J Cancer Care 2016;25:280-93.